Kymeras Partner SNY to Expand Ongoing HS and AD Studies

ADMA Stock  USD 21.47  0.29  1.37%   
About 66 percent of all ADMA Biologics' investors are curious in acquiring. The analysis of the overall investor sentiment regarding ADMA Biologics suggests that a large number of traders are confidant. The current market sentiment, together with ADMA Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use ADMA Biologics stock news signals to limit their universe of possible portfolio assets.
  
Kymera announces expansion plans of ongoing mid-stage studies on KT-474 by partner Sanofi.

Read at finance.yahoo.com
Yahoo News
  

ADMA Biologics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards ADMA Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

ADMA Biologics Fundamental Analysis

We analyze ADMA Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADMA Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADMA Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Retained Earnings

Retained Earnings Comparative Analysis

ADMA Biologics is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.

ADMA Biologics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ADMA Biologics stock to make a market-neutral strategy. Peer analysis of ADMA Biologics could also be used in its relative valuation, which is a method of valuing ADMA Biologics by comparing valuation metrics with similar companies.

Peers

ADMA Biologics Related Equities

MCRBSeres Therapeutics   15.58   
0%
100.0%
FATEFate Therapeutics   5.68   
0%
36.0%
ATRAAtara Biotherapeutics   5.67   
0%
36.0%
ANTXAN2 Therapeutics   3.73   
0%
23.0%
PLRXPliant Therapeutics   3.70   
0%
23.0%
STOKStoke Therapeutics   3.06   
0%
19.0%
AKBAAkebia Ther   2.66   
0%
17.0%
ETNB89bio   2.28   
0%
14.0%
CRBUCaribou Biosciences   2.02   
0%
12.0%
VXRTVaxart   1.67   
0%
10.0%
PLXProtalix Biotherapeutics   1.18   
0%
7.0%
MDGLMadrigal Pharmaceuticals   0.65   
4.0%
0%
RCUSArcus Biosciences   0.95   
6.0%
0%
ACLXArcellx   1.14   
7.0%
0%
INMBINmune Bio   1.44   
9.0%
0%
IBIOIbio   3.03   
19.0%
0%
ANEBAnebulo Pharmaceuticals   4.11   
26.0%
0%
BCRXBioCryst Pharmaceuticals   4.34   
27.0%
0%
SANASana Biotechnology   4.98   
31.0%
0%
TNXPTonix Pharmaceuticals   5.00   
32.0%
0%
TFFPTff Pharmaceuticals   5.88   
37.0%
0%
XFORX4 Pharmaceuticals   8.11   
52.0%
0%
CDTXCidara Therapeutics   8.38   
53.0%
0%

Complementary Tools for ADMA Stock analysis

When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios